Lung cancer has become a leading disease for the tumor-induced mortality. Non-small cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancers. The present research aimed to evaluate the correlation between the anaplastic lymphoma kinase/oncogene or c-ros oncogene 1 (ALK/ROS1) fusions or mutations of epidermal growth factor receptor (EGFR) and ages or gender of patients.
Background
Nowadays, lung cancer has been considered a leading reason for tumor-induced mortality worldwide [1] . Among lung cancers, non-small cell lung cancer (NSCLC) accounts for approximately 80% [2] . In clinical settings, the conventional chemotherapeutic strategy only improves the clinical outcomes for the advanced stages of NSCLC, with a shorter survival time of even less than one-year post diagnosis [3] . A previous study [4] reported that the chromosomal-alteration or the protein-kinase-activation might be a well-known mechanism for tumorigenesis. Until now, a large number of molecule mutations in NSCLS have been discovered, such as fusion of oncogene or c-ros oncogene 1 (ROS1) or fusion of anaplastic lymphoma kinase (ALK) and the mutation of epidermal growth factor receptor (EGFR), [5, 6] .
The mutation of EGFR acts as the most critical driver-gene of NSCLC patients, especially for the east Asian patients [7, 8] . Meanwhile, the EGFR-tyrosine kinase inhibitor could be considered a potential and effective biomarker for the EGFR mutation and frequent induction for NSCLC [9] . The ALK is the first discovered targetable fusion oncokinase; it was identified in only 4% to 6% of NSCLC patients. The most frequent fusion of ALK is the EML4-AKL fusion in clinical settings [10, 11] . ROS1 fusion gene is considered a potential driver for NSCLC and can activate several different downstream signaling pathways. Previous studies reported that the prevalence of ROS1 fusions in NSCLC ranges from 0.9% to 3.7% in clinical settings [12, 13] .
Although the previous studies have described many EGFR mutations, ALK fusions or ROS1 fusions in clinical, there were no investigations for clarifying the distribution of these mutations or fusions in NSCLC patients with different gender and ages. We believed that it was important to further discover the distribution of EGFR mutations or ALK/ROS1 fusions for exploring the mechanism of NSCLC. Therefore, this study involved a total of 1449 NSCLC patients and selected 457 patient with EGFR mutations or ALK/ROS1 fusions for further study.
Material and Methods

Patients and samples
A total of 1449 patients diagnosed as NSCLC at The First Affiliated Hospital of University of Science and Technology of China, Hefei City, P.R, China, between November 2016 and February 2018 were involved in the present research. Among all of these NSCLC patients, the consecutive EGFR mutations or ALK/ROS1 fusions characterized patients (457 cases) were selected for further investigation. The clinical characteristics or parameters for NSCLC patients are illustrated in the Table 1. All of the patients provided written informed consents and approved their participation in this study. The present research was approved by Ethics Committee of The First Affiliated Hospital of University of Science and Technology of China, Hefei City, P.R, China.
EGFR mutations evaluation
The EGFR genes or mutations were detected using the DNA sequencing technique and the amplification-refractory mutation system (ARMS) commercial regent (Amoy, Xiamen, China) according to the manufacturer's construction. In this study, the following mutations were detected: single mutation of exon 19 deletion, exon 20 insertion, exon 21 L858R, exon 21 L861Q, exon 18 G719X, 2 mutations in exon 20 (L858R+T790M, L858R+S768I), 2 mutations in exon 18 and 20 (G719X+S768I), and exon 19 deletion combining the T790M mutation.
Examination of the ALK/ROS1 fusions
The mRNAs of ALK and ROS1 fusion were examined by using the polymerase chain reaction (PCR) technique and fusion gene detection kit (Amoy, Xiamen, China). In brief, total RNAs were extracted with the Qiagen RNeasy kit (Qiagen, Hilden, Germany) and were transcribed into the cDNA by using the Reverse Transcription kit (Invitrogen/Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. The conditions for PCR were the followings: denaturation for 5 minutes at 95°C, followed by 94°C for 25 seconds, 65°C for 20 seconds and 72°C for 20 seconds, and for 35 cycles. The data collection and sensitivity analysis were conducted as described in a previous study [14] .
Statistical analysis
SPSS software (version 20.0, SPSS, Chicago, IL, USA) was used for all statistical analyses in this study. The quantitative data were recorded as mean values ± standard deviation (SD) and analyzed by using the Student's t-test for analysis between 2 groups. Meanwhile, Tukey's post hoc test was used to validate ANOVA for comparing measurement data among groups.
The categorical variables (recorded as percentage) were analyzed and compared by employing the chi-square test. P<0.05 was assigned as a statistical significance.
Results
Characteristics of patients with EGFR mutation
In summary, 417 NSCLC patients were involved and selected for the EGFR mutation analysis and the characteristics are listed in Table 1 . Among these patients, there were 168 males and 249 females ( Table 1 ). The results showed that the females suffered from EGFR mutations more frequently. Meanwhile, there were no significant differences for the EGFR mutations between patients younger than 60 years old and older than 60 years old ( 
Characteristics of patients with ALK/ROS1 fusion
In this study, 40 NSCLC patients were involved and selected for the ALK/ROS1 fusion analysis; the characteristics are listed in Table 2 . Among these patients, there were 18 males and 22 females, and there were significant differences (Table 1 , P=0.041).
The data illustrated that the females were for frequently found to have the ALK/ROS1 fusions. Meanwhile, the occurrence of ALK/ROS1 fusion was more frequent in <60 years of age patients compared to patients older than 60 years of age (Table 1 , P=0.024). For the ALK fusions, there were 19 EML4-ALK-1 fusion cases, 7 ALK-1 mutation cases, 2 EML4-ALK-3 fusion cases, and 2 ALK mutation cases (Table 2 ). There were significant differences for the ALK fusions among different fusion types (Table 2 , P=0.013). For the ROS1 fusion, there were 4 cases of ROS1-1, 5 case of ROS1-2, and 1 case of ROS1-1+ROS1-2, among which no significant differences appeared ( (Table 4) .
Comparison for distribution of ALK/ROS1 in different genders
To evaluate the distribution of ALK/ROS1 fusions in different genders, the ALK fusion (EML4-AKL-1, EML4-ALK-1 mutation, EML4-ALK-3, and EML4-ALK mutation) and ROS1 fusion 
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(CD74-ROS1-1 and EZR-ROS1-2), were detected. The results showed that there were no significant differences for these fusions between males and females (Table 5 , P>0.05).
EML-ALK-1 existed in the females of NSCLC patients
The analysis of ALK fusions showed that the EML4-ALK-1 fusion (12 cases) mainly was distributed in patients <60 years of age. However, there were only 7 cases of EML4-ALK-1 fusion in patients ³60 years of age, which was significantly fewer compared to patients <60 years of age (Table 6 , P=0.039). Moreover, there were no significant difference for the EML4-ALK-1 mutation, EML4-ALK-3 mutation, EML4-ALK mutation, CD74-ROS1-1 and EZR-ROS1-2 fusions between patients ³60 years of age and patients <60 years of age (Table 6 ).
Discussion
The EGFR mutations are critical due to their predictive capabilities for targeting therapy in NSCLC [15] . ALK rearrangements or fusions have been discovered in the samples of NSCLC patients and are also the targeting site for cancer therapy [10] . Therefore, in cases of advanced NSCLC, detecting EGFR mutations and ALK/ROS1 fusions strongly suggests conduct targeting therapy [16] . Therefore, the EGFR mutations and ALK/ROS1 fusions are important drivers for the initial evaluation of the NSCLC.
In the present study, EGFR gene mutations were examined in 417 NSCLC patients; and ALK/ROS1 fusions were detected in 40 NSCLC patients. The EGFR mutations frequency in female patients were significantly higher compared to that in male patients, and the frequency of the ALK/ROS1 fusions in females were also significantly higher compared to that in males. The EGFR mutations and ALK fusions have not, to our knowledge, been investigated or clarified. However, for the ROS1 fusions, a previous study [17] reported that the frequency of ROS1 in women was higher than that in men, which is consistent with our results of ROS1 fusions. Meanwhile, cases of ALK/ROS1 fusions in patients <60 years of age were significantly higher compared to patients ³60 years of age. However, there were no significant differences for the EGFR mutations between patients <60 years of age and patients ³60 years of age. These results suggested that the EGFR mutations and the ALK/ROS1 fusions were closely correlated with the pathogenesis of NSCLC in clinical settings these findings were in accord with the speculation of the previous study described [18, 19] .
Until now, studies [20, 21] 
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<60 years of age. These results suggested that female NSCLC patients and patients older than 60 years of age, it was relatively common to be inflicted by the EGFR mutations, as suggested by previous studies [22] .
The ALK/ROS1 fusion genes have been used for detecting NSCLC patients harboring EGFR mutation samples and applied to therapeutic efficacy [23] . The fusion of ALK was found in a relatively small number of patients with NSCLC [24] , however, little is known about the ALK fusion distribution in different ages and genders. In addition, many gene fusion partners were discovered, including EZR, CD74, SLC34A2, TPM3, and LRIG3 [12] , all of which could fuse with the ALK or ROS1. In this study, there were no significant differences for all of the aforementioned fusions between males and females. The EML4-ALK-1 fusion (12 cases) was mainly distributed in patients <60 year of age, and was more significant compared to patients ³60 years of age. These findings hint that the EML4-ALK-1 fusion mainly distributed in the NSCLC patients <60 year of age.
Conclusions
Females were often inflicted by the EGFR mutations, especially for the exon 19 deletion and L858R mutation. There were significantly more ALK/ROS1 fusions in females compared to that in males and significantly more ALK/ROS1 fusions in patients <60 years old compared to patients older than 60 years of age. Exon 21 L858R and L861Q dominantly occurred in patients ³60 years of age and exon 19 deletion in patients <60 years of age. EML-ALK-1 mainly existed in female NSCLC patients. Therefore, EGFR mutations and ALK/ROS1 fusions mainly were found in NSCLC female patients who were older than 60 years of age.
